Integrating Emerging Evidence to Improve Recognition, Diagnosis, Early Intervention, and Long-term Management of Progressive Fibrosing Interstitial Lung Disease

 
Tuesday, October 9, 2018
5:45 AM – 7:15 AM
 
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX
Room: Salon IJ
 
Faculty
Kevin R. Flaherty, MD, MS, FCCP
Professor of Medicine
Division of Pulmonary & Critical Care Medicine
University of Michigan
Ann Arbor, MI
 
Lisa H. Lancaster, MD
Associate Professor of Medicine
Medical Director, Interstitial Lung Disease Program
Division of Allergy, Pulmonary, and Critical Care Medicine
Vanderbilt University Medical Center
Nashville, TN
 
This symposium is not supported, endorsed, or accredited by the American College of Chest Physicians.

This activity is provided by Paradigm Medical Communications, LLC.  
 
Target Audience
This activity has been designed to meet the educational needs of pulmonologists, radiologists, and pathologists. It may also be of benefit to primary care physicians, PAs, nurse practitioners, nurses, pharmacists, fellows, residents, and other healthcare professionals interested in the management of interstitial lung disease (ILD).
 
Statement of Need
Interstitial lung disease is progressive and severely debilitating. Clinicians need to understand the signs and symptoms of ILD and be able to distinguish among different types, particularly those associated with a progressive phenotype, including inflammatory connective-tissue diseases (eg, rheumatoid arthritis) and chronic hypersensitivity pneumonitis, as well as unclassified ILD to better diagnose, monitor, and manage disease and maintain quality of life. The goal of this activity is to improve recognition and diagnosis of ILD with a progressive phenotype, and to improve management of these patients through integration of traditional and newer therapy options into routine practice.
 
Learning Objectives
Upon proper completion of this activity, participants should be better able to:
  • Identify diseases most commonly associated with interstitial lung disease with a progressive lung disease phenotype that necessitate monitoring for lung involvement.
  • Interpret presenting signs and symptoms to diagnose interstitial lung disease with a progressive lung disease phenotype.
  • Assess the implications of recent and ongoing clinical research for the treatment of interstitial lung disease with progressive phenotype.
Agenda
5:45 AM – 6:15 AM
 
Registration and Complimentary Buffet Breakfast
 
6:15 AM – 7:15 AM

 
 
 
 
 
 
Clinical Program
  • Introduction and Case Presentation
  • Identification and Monitoring of Patients at Risk of PF-ILD: Connective-tissue disease (CTD) and chronic hypersensitivity pneumonitis (HP)
  • Differential Diagnosis and Classification of PF-ILD
  • Recent Research on Clinical Management of PF-ILD
  • Q&A and Discussion











Physician Accreditation Statement
Paradigm Medical Communications, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Physician Credit Designation Statement
Paradigm Medical Communications, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
 
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
 
Disclosure of Commercial Support
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Disclosure of Conflicts of Interest
In accordance with ACCME requirements on disclosure, information about relationships with commercial interests (if any) for anyone contributing to content development will be included in materials distributed at the time of the activity.
 
Registration
To register for this complimentary symposium, please click Continue below or call toll-free: (877) 252-5100, ext. 1.